MENU

Projects

Japan Agency for Medical Research and Development

Project name

"Nanomedicine"- FY 2018 Japan-Spain Joint call for Strategic International Collaborative Research Program (SICORP)

Research and Development Theme

Drug delivery targeting Brain CPT1: a novel nanomedicine-based approach to fight obesity and cancer (COnCorD)

Time Period

Jan. 1, 2019 ~ Dec. 31, 2021

Research and Development Representative

Senior Research Scientist
Innovation Center of NanoMedicine
Sabina Quader

Research and Development Representative (Spain)

Universidad Internacional de Cataluña
Rosalía Rodríguez-Rodríguez

Outline

To develop and use of new nanomedicine-based therapeutic approaches directed to specific cells of the brain and to fight against obesity and brain tumors focusing on the brain lipid metabolism’s key enzyme CPT1.


Project name

Research Program on Hepatitis
Research on the Innovative Development and the Practical Application of New Drugs for Hepatitis B

Research and Development Theme

Comprehensive development of innovative therapeutics aiming at complete inactivation of HBV genome in liver by genome editing technology applicable to personalized medicine

Co-Research and Development Theme

Development of RNA carrier targeting the liver

Time Period

FY2017-FY2021

Research and Development Representative

Project Leader
Genome Medical Science Project, Research Institute,
The Research Center for Hepatitis and Immunology Department of Liver Diseases,
National Center for Global Health and Medicine
Masashi Mizokami

Co-Researcher

Director General of the Innovation Center of NanoMedicine
Kazunori Kataoka

Outline

Our aim is to treat Hepatitis B by liver specific delivery of a messenger RNA (mRNA) encoding a genome editing enzyme to inactivate the hepatitis B virus genome. To achieve this goal, mRNA should be efficiently delivered to hepatocytes after intravenous injection, while avoiding clearance mechanisms and degradation during circulation. We are designing innovative nanomachines to protect and deliver mRNA.


Project name

"Project for Cancer Research And Therapeutic Evolution" (P-CREATE)

Research and Development Theme

Development of innovative cancer treatment methodologies based on drug delivery system

Co-Research and Development Theme

Development of nanoDDS for delivery of tumor microenvironment-targeted drugs and nucleic acids medicines.

Time Period

Apr. 1, 2016 - Mar. 31, 2021

Research and Development Representative

Professor, Tokyo Institute of Technology
Nobuhiro Nishiyama

Co-Researcher

Director General of the Innovation Center of NanoMedicine
Kazunori Kataoka

Outline

In this project, we are developing 3 key technologies, nano-scaled drug delivery systems (nanoDDS), new drug candidates and evaluation methodologies through multidisciplinary collaboration by experts of DDS, molecular oncology and clinical oncology.  This project is aimed to realize innovative cancer diagnostic and therapeutic systems targeting the network of cancer cells. The role of the researchers in iCONM is to develop nanoDDS for new drug candidate and establish their evaluation methods utilizing in vivo confocal laser scanning microscopy.


<< Past Projects >>

Project name

Research Program on Hepatitis
Research on the Innovative Development and the Practical Application of New Drugs for Hepatitis B

Research and Development Theme

Development of new therapy for the elimination of HBV DNA in the liver based on gene editing and nano delivery systems

Co-Research and Development Theme

Development of liver-targeting drug delivery system

Time Period

Apr. 1, 2016 - Mar. 31, 2017

Research and Development Representative

Project Leader
Genome Medical Science Project, Research Institute
National Center for Global Health and Medicine
Masashi Mizokami

Co-Researcher

Director General of the Innovation Center of NanoMedicine
Kazunori Kataoka

Kawasaki Institute of Industrial Promotion
Principal Research Scientist at the Innovation Center of NanoMedicine
Keiji Itaka

Outline

We develop liver-targeting mRNA delivery system aiming at a new therapy for the elimination of HBV DNA in the liver. We design the mRNA-loaded nanomachine, evaluate its transfection efficiency and safety, and investigate the the therapeutic effect on HBV-infected model mice.


Project name

Practical Research for Innovative Cancer Control
Part3:  Research and development of new drug to fulfill unmet medical needs

Research and Development Theme

Practical application for a novel nucleoside therapy targeting PRDM14 to overcome intractable breast and pancreatic cancer.

Co-Research and Development Theme

Development of delivery system for nucleic acids medicine

Time Period

Apr. 1, 2016 - Mar. 31, 2017

Research and Development Representative

Project Associate Professor, Center for Antibody and Vaccine Therapy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo
Hiroaki Taniguchi

Co-Researcher

Director General of the Innovation Center of NanoMedicine
Kazunori Kataoka

Outline

This project is aimed to develop new nucleic acids medicine targeting PRDM14 for the treatment of intractable triple negative breast cancer and pancreatic cancer. We are developing polymeric delivery system of siRNA targeting PRDM14.


Project name

Practical Research for Innovative Cancer Control
Part3:  Research and development of new drug to fulfill unmet medical needs

Research and Development Theme

Research on development of innovative therapeutic methods targeting solid cancer stem cells

Co-Research and Development Theme

Development of drug delivery system (DDS) which targeted at CD44 pathway of Cancer stem cells.

Time Period

Apr. 1, 2016 - Mar. 31, 2017

Research and Development Representative

Osaka University, Graduate School of Medicine, Department of Gastroenterological Surgery,
Professor Masaki Mori

Co-Researcher

Director General of the Innovation Center of NanoMedicine
Kazunori Kataoka

Outline

This project is aimed to develop new therapeutic methods to eradicate cancer stem cells towards overcoming intractable digestive cancers such as pancreatic cancer and metastatic colon cancer. We are developing drug delivery system for targeting cancer stem cells.


Project name

Practical Research for Innovative Cancer Control
Part3:  Research aiming at reinforcing scientific basis and developing to next phase for practical application of innovative cancer diagnostic and therapeutic drugs

Research and Development Theme

Clinical development of nucleic acid medicine for refractory gastrointestinal cancer

Co-Research and Development Theme

Evaluation of DDS (OUM302)

Time Period

Apr. 1, 2017 - Mar. 31, 2019

Research and Development Representative

Professor, Department of Gastroenterological Surgery, Graduate School of Medicine,
Osaka University
Mori Masaki

Co-Researcher

Director General of the Innovation Center of NanoMedicine
Kazunori Kataoka

Outline

We screen effective nucleic acid medicine for refractory gastrointestinal cancer and enclose it in a drug delivery system.  Then we develop nucleic acid medicines with high antitumor effecacy by protection of nucleases in the blood and accumulation in cancer. And we proceed a doctor-initiated clinical trial.


Project name

the Strategic Research Program for Brain Sciences (the SRPBS)
Integrated Research on Depression, Dementia and Development Disorders

Research and Development Theme

Molecular imaging diagnosis of Alzheimer’s disease through the creation of blood-brain barrier-crossing beta-amyloid oligomer antibody, Explaining development of the treatment and pathogenic mechanism

Co-Research and Development Theme

Structural and functional evaluation of GLUT1 bound ligand molecule that allows for efficient delivery of antibodies within the brain

Time Period

Apr. 1, 2016 - Mar. 31, 2020

Research and Development Representative

Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
Professor Takanori Yokota

Co-Researcher

Director General of the Innovation Center of NanoMedicine
Kazunori Kataoka

Kawasaki Institute of Industrial Promotion
Visiting Scientist at the Innovation Center of NanoMedicine
Yasutaka Anraku

Outline

This theme has a focus on the creation of a BBB-crossing ABO antibody, using the Aβ oligomer antibody (ABO antibody) that team researcher Mr. Matsubara - who is in Phase I in the U.S. - developed, and narrowed the focus to the beta-amyloid (Aβ) oligomer, which is a probable pathogenetic molecule of Alzheimer’s Disease (AD) as the target molecule. Also, the development an Aβ oligomer PET/MRI and giving a diagnosis while analyzing Aβ oligomer pathology.

The results show that it is now possible to diagnose of early onset - and before pathogenesis - of AD, and sort out which patients are to be treated, as well as the development of a companion diagnostic that makes it possible for repeat evaluation. This will make a “theranostics drug” that has both therapeutic and diagnostic functions a reality, which will be innovative and ideal dimentia drug development that agrees with advanced innovative drug development concepts that next-generation innovative drug development demands.


Project name

Technology development program for countermeasures against viruses and other infectious diseases

Research and Development Theme

Development of a portable rapid testing device for the virus infectious diseases

Time Period

2020.12-2021.3

Research and Development Representative

The graduate school of engineering, Department of materials engineering, University of Tokyo, Professor
Takanori Ichiki

Co-Researcher

Deputy Principal Research Scientist
Innovation Center of NanoMedicine
Shingo Ueno

Outline

Development of a prototype of portable rapid testing device for the virus infectious diseases and quantitative verification of its usefulness.